ResMed meets estimates on steady demand for its sleep apnea devices
Aug 1 (Reuters) -Medical equipment maker ResMed RMD.N reported fourth-quarter revenue in line with estimates on Thursday, on steady demand for its sleep apnea treatment devices.
The company's quarterly revenue rose 9% to $1.22 billion, in line with estimates of $1.22 billion.
ResMed makes ventilators and machines that provide continuous and bilateral positive airway pressure, known as CPAP and BIPAP, which are used for non-invasive treatment of sleep apnea.
Sleep apnea is a condition where the airway gets blocked multiple times while sleeping.
The California-based company reported adjusted profit of $2.08 per share for the quarter ended June 30, narrowly beating estimates of $2.07per share, according to LSEG data.
Separately, Eli Lilly LLY.N said in June that its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials.
ResMed has previously shrugged off concerns over weight-loss drugs such as Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's Zepbound being tested to treat sleep apnea.
Shares of the company were down 4.7% at $204.51 after the bell.
Reporting by Unnamalai L and Sneha S K in Bengaluru; editing by Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
